Keros Therapeutics completed its cash tender offer to repurchase up to 10,950,165 shares of common stock at $17.75 per share, totaling approximately $194.4 million. More shares were tendered than the company could purchase, resulting in a pro-rata allocation.

Keros Therapeutics completed a cash tender offer to repurchase up to 10,950,165 shares of its common stock at $17.75 per share, totaling approximately $194.4 million. More shares were tendered than the target, so shares will be accepted on a pro rata basis.

Over 25 pharmaceutical companies are developing TGF-β inhibitor drugs targeting oncology and fibrosis treatments, with promising pipeline therapies showing potential for addressing significant unmet medical needs.

Keros Therapeutics announced that leading independent proxy advisory firm Glass Lewis recommended that Keros stockholders vote 'FOR' all three of the company's director nominees for the upcoming Annual Meeting. Keros stated that the board is best equipped to oversee the strategic review process and execute on the ultimate outcome.

The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, monoclonal antibodies, and personalized medicine is transforming treatment outcomes.

Harley-Davidson is exploring strategic alternatives for its financing unit, while Capri Holdings is selling Versace to Prada for $1.375 billion. Several other companies, including Impresoft, Keros Therapeutics, and Rivalry Corp., are also exploring strategic alternatives.

Keros Therapeutics has initiated a formal review of strategic alternatives, including a potential sale, after an investor gained an 11.2% stake in the company. The company has also adopted a stockholder rights plan.

Keros Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO will participate in upcoming healthcare conferences. The company is focused on developing novel therapeutics to treat disorders linked to dysfunctional signaling of the TGF-β family of proteins.

Oppenheimer initiated coverage on Keros Therapeutics Inc (NASDAQ:KROS), a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Oppenheimer writes, “Keros is developing best-in-class therapeutics that regulate TGF-β signaling to treat hematological and cardiopulmonary diseases. We consider its pipeline one of the more attractive in biotech today, given its disease-modifying potential in indications with considerable unmet need.” Keros’ lead product candidate, KER-050 (elritercept), is being developed for low blood cell counts or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis. The analyst sees elritercept as the potential preferred 2L treatment in MDS with durable responses and benefits. At the EHA update, an overall hematologic response was ...Full story available on Benzinga.com

LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced changes to its Board of Directors (“Board”) and Executive Committee, effective July 1, 2024.

LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it presented additional data from its two ongoing Phase 2 clinical trials of elritercept (KER-050), one in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (“MDS”) and one in patients with myelofibrosis (“MF”), at the 29th Annual Hybrid Congress of the European Hematology Association (“EHA”), held in person in Madrid, Spain and virtually from June 13 through 16, 2024. In addition, Keros presented preclinical data showing that, in an animal model of MF, a research form of elritercept promoted erythropoiesis, mitigated anemia associated with MF, improved anemia associated with ruxolitinib therapy and improved muscle mass and function.

Stay updated on Wall Street news with our daily podcast available on Seeking Alpha, iTunes, and Spotify.